TechValidate Research on Getinge

These pages present data that TechValidate has sourced via direct research with verified customers and users of Getinge. TechValidate stands behind the authenticity of all published data. Learn more »

124 Customers Surveyed

411 Data Points Collected

13 Published TechFacts

4 Published Charts

Selected Research Highlights

Getinge Customer Research

The design of the IABP SHOCK II trial has several limitations. We still need contemporary data to determine the role of IABP therapy in cardiogenic shock from Acute MI.

True: 81%
False: 19%

Getinge Customer Research

How comfortable and confident would you say members of your team are in caring for patients receiving IABP therapy.

Very comfortable and confident
Somewhat comfortable and confident
Extremely comfortable and confident
Not comfortable and confident

Getinge Customer Fact

Zenaida Carbon believes that using inotropes with IABP therapy should be done with caution as their mechanism of action may negate the positive effects of IABP therapy and therefore limit the balloon pumps effectiveness since they negatively affect the myocardial oxygen consumption.

Getinge Customer Satisfaction

81% of surveyed professionals are likely to recommend Getinge.*

More to Explore

About Getinge

Saving lives is the greatest job in the world. Everything we do, from architectural planning to the equipment, therapies and solutions aim to secure the safest and most reliable care. As a leading medtech company, we focus every talent and resource towards helping our customers save as many lives as possible.

Getinge Website   Getinge Website